Tagged with Ipsen

China Alan Chen, general manager for Ipsen China, shares the exciting journey of Ipsen in China in the past few years as the third-largest affiliate for the group globally,  upcoming innovative product launches, the reorganization and HR strategy he has headed to take Ipsen China to the next stage of its…

Top 10 Geoffrey Guy, David Meek, Tae Han Kim, Pierre Moustial, Vivek Sharma, Antonio Portela and many other remarkable people that are shaping the global life sciences industry shared with PharmaBoardroom valuable insights on the companies they lead and their vision for the future.   Geoffrey Guy Geoffrey Guy is the chairman and founder…

France Ipsen CEO David Meek provides a fascinating look into the French pharmaceutical ecosystem, Ipsen’s bold global expansion plans, its R&D transformation, and the exciting changes to come.   “From our roots as a French company, we have blossomed into a growing international player within the areas of oncology, neuroscience and…

Algeria A sudden imposition of import restrictions on pharmaceuticals in 2017 has pushed several multinational companies to establish local production facilities in Algeria. However, the localization process can be fraught both for companies that establish direct manufacturing footprints via joint ventures and those that employ the services of local contract manufacturers.…

France Ipsen global CEO David Meek provides a fascinating look into the French pharmaceutical ecosystem, Ipsen’s bold global expansion plans, its R&D transformation, and the exciting changes to come.   From our roots as a French company, we have blossomed into a growing international player within the areas of oncology, neuroscience…

UK For French mid-cap Ipsen, the UK is one of three global hubs, with manufacturing in Wales, large-scale R&D activities near Oxford as well as UK Commercial Operations and global functions including HR, Tech Ops and Commercial Operations in Slough, near London. With ten percent annual growth to reach GBP 80…

Ipsen For Ipsen, the UK is one of three global hubs, with manufacturing in Wales in which it is continuously investing, as well as large-scale R&D activities near Oxford. Ipsen’s general manager for the UK and Ireland, Ewan McDowall, tells us the company’s focus remains on attracting and developing great talent,…

Spain The managing director of the Spanish affiliate of one of France’s most exciting and ambitious mid-caps speaks out about crafting a commercial powerhouse and efficient launch machine in oncology, and shares the secrets of deftly managing organizational change.    How would you describe Ipsen´s legacy and footprint within the Spanish…

Canada Lyndal Walker of Ipsen Canada discusses the opportunities present in the Canadian pharma market for a mid-cap innovator like Ipsen, the value of Canada’s research ecosystem, and emerging healthcare trends within the country. Lyndal, you established Ipsen’s Canadian affiliate in 2015. First and foremost, what opportunity did Ipsen globally see…

Ipsen These are exciting times for Ipsen in Ireland, with plans to expand the company’s already significant API manufacturing footprint to deal with increasing global demand for its products. “Sales from [Somatuline® (lanreotide) and Decapeptyl® (triptorelin)] amounted to over EUR 700 million in 2015, which was over half of Ipsen’s global…

Manufacturing James Byrne, VP Site for Ipsen Manufacturing Ireland, discusses the strategic importance of the Ireland site as the sole provider of peptides for products generating over 50 percent of Ipsen’s global revenues; his strategy for attracting and retaining the best talent; and his thoughts on the impact of new manufacturing…

France Marc de Garidel reveals how 2015 has been Ipsen’s best year since becoming publicly traded, marked by their take-off in the US, and how in 2016 the US will overtake France to become their number one affiliate. Mr de Garidel also explains Ipsen’s key growth drivers for the next five…